Peripheral Arterial Disease Trial, Recruiting NCT06410521 Sponsor: University of Trás-os-Montes and Alto Douro Condition: Peripheral Arterial Disease
Back to Peripheral Arterial Disease

Peripheral Arterial Disease Trial, Recruiting

NCT06410521
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with peripheral artery disease (PAD) that is currently stable
  • A specific blood flow test (comparing blood pressure in your ankle to your arm) shows a reading between 0.41 and 0.90 in one or both legs
  • You have mild to moderate leg pain when walking (classified as Fontaine Stage IIa or IIb — confirm with trial site if unsure which stage applies to you)
  • You have a history of leg pain that comes on during walking
  • Your walking leg pain has been confirmed during a treadmill test
  • You are able to give written consent to take part

Who may not be able to join:

  • Your arteries are stiff or calcified, shown by an ankle-to-arm blood pressure reading of 1.4 or higher
  • You have taken certain medications for leg pain (such as Cilostazol or Pentoxifylline) in the last 3 months
  • You have previously had a procedure on your leg arteries, such as a stent, balloon treatment, or bypass surgery, or have taken part in a supervised exercise programme before
  • You are unable to walk on a treadmill at a speed of 3.2 km/h (2 mph)
  • You have taken part in a clinical trial or exercise programme in the past 3 months
  • Your PAD causes no symptoms at all
  • Your ability to exercise is mainly limited by a condition other than leg pain when walking
  • You have chest pain (angina), heart failure, a chronic lung condition, severe arthritis, or have had a limb amputation

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Catarina Abrantes, Ph.D., University of Trás-os-Montes and Alto Douro, Vila Real, Portugal

Phone: 259350000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Trás-os-Montes and Alto Douro
Registry
ClinicalTrials.gov
Start date
20 June 2025
Est. completion
1 December 2027

Where this trial is recruiting

🇵🇹 Portugal

Primary endpoints

Pain-free walking distance; Maximum walking distance; Percentage of muscle deoxygenation; Muscle reoxygenation time

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov